3.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VTYX Giù?
Forum
Previsione
Ventyx Biosciences Inc Borsa (VTYX) Ultime notizie
What analysts say about Ventyx Biosciences Inc. stockExceptional profit velocity - PrintWeekIndia
Ventyx Biosciences Inc. Stock Analysis and ForecastRapid market gains - PrintWeekIndia
How Ventyx Biosciences Inc. stock performs during market volatilityPredictable Return Stock Picks - Newser
Is Ventyx Biosciences Inc. a good long term investmentUnrivaled growth potential - Autocar Professional
What drives Ventyx Biosciences Inc. stock priceTremendous growth opportunities - jammulinksnews.com
Why Ventyx Biosciences Inc. stock attracts strong analyst attentionSmart Return Focused Trading - Newser
Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth? - Yahoo Finance
What makes Ventyx Biosciences Inc. stock price move sharplyFree Insider Trading Tips - Newser
Wealth Enhancement Advisory Services LLC Invests $28,000 in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Analyzing the Impact of Earnings Reports on Ventyx Biosciences Inc Inc. (VTYX) Price Performance - investchronicle.com
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Ventyx Biosciences, Inc. (VTYX) Shareholders - ACCESS Newswire
Ventyx Biosciences, Inc.(NasdaqGS: VTYX) dropped from Russell 3000E Index - MarketScreener
Ventyx Biosciences, Inc.(NasdaqGS: VTYX) dropped from Russell 3000 Value Index - MarketScreener
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Rhumbline Advisers - Defense World
Canaccord maintains buy rating on Ventyx stock after positive trial results - Investing.com
Ventyx stock steady as Parkinson’s drug shows biomarker reductions By Investing.com - Investing.com India
Ventyx reports positive outcomes from trial of VTX3232 for Parkinson’s - Yahoo Finance
Ventyx Therapeutics' VTX3232: A Neuroinflammation Breakthrough with Orphan Drug Pricing Power - AInvest
Ventyx Biosciences Inc’s Mixed Bag: Down -9.22% in 6 Months, Down 58.21% in 30 Days - investchronicle.com
Ventyx Biosciences Holds Steady Despite Encouraging Early Parkinson’s Trial Results - MSN
Ventyx Biosciences Announces Positive Top-Line Data from - GlobeNewswire
Ventyx Biosciences Shares Fall After Tier 2 Exploratory Biomarkers Remain Stable in Parkinson's Study - MarketScreener
Ventyx reports positive Phase 2a results for Parkinson’s drug - Investing.com
Ventyx Biosciences Insiders Placed Bullish Bets Worth US$1.26m - Yahoo.co
Ventyx Biosciences' Study of VTX3232 Met Safety, Tolerability Objectives - MarketWatch
Ventyx posts mid-stage trial win for Parkinson’s drug (VTYX) - Seeking Alpha
Ventyx Biosciences stock trades flat despite positive parkinson’s drug trial data - Investing.com Canada
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):